K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
- PMID: 8342602
- PMCID: PMC1887038
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
Abstract
We examined 82 surgically resected or biopsied, formalin-fixed, paraffin-embedded primary adenocarcinomas of the pancreas for the presence of activating point mutations in codon 12 of the K-ras oncogene. Mutations were detected using primer-mediated, mutant-enriched, polymerase chain reaction-restriction fragment length polymorphism analysis and characterized further by allele-specific oligonucleotide hybridization. This combination of mutant-enriched polymerase chain reaction-restriction fragment length polymorphism analysis and allele-specific oligonucleotide hybridization results in a rapid and sensitive characterization of the mutations in codon 12 of K-ras. Sixty-eight (83%) of the 82 carcinomas examined harbored a point mutation. Of the 68 mutations, 33 (49%) were guanine to adenine transitions, 27 (39%) were guanine to thymine transversions, and eight (12%) were guanine to cytosine transversions. Mutations were found in carcinomas of the head (61 of 75, 81%) as well as in carcinomas of the body or tail (seven of seven, 100%) of the pancreas. The overall prevalence of K-ras point mutations in adenocarcinomas of the pancreas obtained from patients who smoked cigarettes at some point during their lives (88%; 86% in current smokers and 89% in ex-smokers) was greater than that seen in pancreatic adenocarcinomas from patients who never smoked cigarettes (68%, P = 0.046). The presence of K-ras point mutations did not correlate with tumor ploidy, tumor proliferating index, or patient survival. These results demonstrate that primer-mediated, mutant-enriched polymerase chain reaction-restriction fragment length polymorphism analysis combined with allele-specific oligonucleotide hybridization can be used to detect and characterize mutations in codon 12 of the K-ras oncogene in formalin-fixed, paraffin-embedded tissues, and the results confirm that activating point mutations in codon 12 of the K-ras oncogene occur frequently in adenocarcinomas of the pancreas.
Similar articles
-
Molecular genetics of malignant insulinoma.Anticancer Res. 1996 Jul-Aug;16(4A):1707-17. Anticancer Res. 1996. PMID: 8712689
-
Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.Clin Cancer Res. 1995 Mar;1(3):359-65. Clin Cancer Res. 1995. PMID: 9815992
-
Patterns of K-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing.J Gastroenterol Hepatol. 2005 Jan;20(1):67-72. doi: 10.1111/j.1440-1746.2004.03542.x. J Gastroenterol Hepatol. 2005. PMID: 15610449
-
Clinical significance of ras oncogene activation in human lung cancer.Cancer Res. 1992 May 1;52(9 Suppl):2665s-2669s. Cancer Res. 1992. PMID: 1562997 Review.
-
[Mutation of the K-ras oncogene in pancreatic carcinoma, and application of its detection in pancreatic juice to diagnose pancreatic carcinoma].Nihon Rinsho. 1995 Feb;53(2):511-7. Nihon Rinsho. 1995. PMID: 7699881 Review. Japanese.
Cited by
-
Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.Methods Mol Biol. 2013;980:175-203. doi: 10.1007/978-1-62703-287-2_9. Methods Mol Biol. 2013. PMID: 23359154 Free PMC article.
-
High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis.Br J Cancer. 2007 Aug 20;97(4):523-30. doi: 10.1038/sj.bjc.6603878. Epub 2007 Jul 10. Br J Cancer. 2007. PMID: 17622249 Free PMC article.
-
Role of ES cell-expressed Ras (ERas) in tumorigenicity of gastric cancer.Am J Pathol. 2010 Aug;177(2):955-63. doi: 10.2353/ajpath.2010.091056. Epub 2010 Jun 21. Am J Pathol. 2010. PMID: 20566745 Free PMC article.
-
Novel therapies for pancreatic adenocarcinoma.Curr Oncol Rep. 2004 May;6(3):199-206. doi: 10.1007/s11912-004-0050-1. Curr Oncol Rep. 2004. PMID: 15066231 Review.
-
Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions.Br J Cancer. 2003 Jan 27;88(2):217-22. doi: 10.1038/sj.bjc.6600734. Br J Cancer. 2003. PMID: 12610506 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous